ArticleAnnals of medicine and surgery (2012)2025
Identification of potential molecular targets for thyroid cancer using multiple-omics analysis and machine learning.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer is the most prevalent endocrine tumor, with increasing incidence rates annually. Identifying novel molecular markers is crucial for early diagnosis and personalized treatment. Design and methods: Differentially expressed genes (DEGs) from thyroid cancer microarray data were analyzed, functional enrichment analysis was performed, and machine learning was used to identify signature genes. Weighted gene co-expression network analysis (WGCNA) was applied to determine key modules associated with thyroid cancer. The expression and correlation of identified genes were analyzed, and their immune infiltration and clinical characteristics were assessed. Single-cell RNA transcriptomics was used to analyze the expression patterns of genes. The expression levels of candidate genes in thyroid cancer specimens were verified by immunohistochemistry and RT-PCR. Results: A total of 348 DEGs were identified, with 18 feature genes selected by machine learning. WGCNA revealed 12 key genes associated with thyroid cancer. Among these, ERO1B, FN1, and CRABP1 were significantly linked to clinical features, patient survival, and tumor immune infiltration. Single-cell RNA transcriptomic analysis showed distinct expression patterns for these genes across different cell types. To verify our findings, the immunohistochemical and RT-PCR results showed that the expression of CRABP1 was significantly downregulated, and the expression of FN1 was significantly upregulated in thyroid cancer tissues. Conclusion: FN1 and CRABP1 were identified as potential molecular targets in thyroid cancer. These genes influence tumor progression, immune response, and patient prognosis, offering new insights for early diagnosis and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.